Janux Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 11, 2025. Janux Therapeutics, Inc. is a Delaware corporation with its principal executive offices in San Diego, California. The company's common stock trades on the Nasdaq Global Market under the symbol "JANX".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (April 17, 2025), 59,168,490 shares were outstanding. 56,239,312 shares were present or represented by proxy at the meeting. Stockholders approved all four proposals:
- Proposal 1 (Election of Directors): Three Class I directors were elected to serve until the 2028 Annual Meeting.
- David Campbell, Ph.D.: 44,740,538 votes for; 9,631,829 withheld.
- Ron Barrett, Ph.D.: 44,005,362 votes for; 10,367,005 withheld.
- Winston Kung: 42,187,543 votes for; 12,184,824 withheld.
- Proposal 2 (Ratification of Auditors): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 56,152,990
- Votes Against: 27,381
- Abstentions: 58,941
- Proposal 3 (Say-on-Pay): Advisory vote on executive compensation was approved.
- Votes For: 53,205,989
- Votes Against: 1,150,947
- Abstentions: 15,431
- Proposal 4 (Frequency of Say-on-Pay): Stockholders approved an annual (1-year) frequency for future advisory votes on executive compensation.
- 1 Year: 53,985,296 votes
- 2 Years: 3,614 votes
- 3 Years: 288,765 votes
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the re-election of the Class I directors and the level of shareholder support (votes withheld) for each candidate.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2025 fiscal year.
- Note the shareholder preference for annual advisory votes on executive compensation.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.